8-K

                      SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C. 20549

                                FORM 8-K

                              CURRENT REPORT

                  PURSUANT TO SECTION 13 OR 15(d) OF THE
                     SECURITIES EXCHANGE ACT OF 1934

    Date of report (Date of earliest event reported): June 10, 2009

                            TECHNE CORPORATION
             (Exact Name of Registrant as Specified in Charter)


       Minnesota                     0-17272             41-1427402
(State or Other Jurisdiction       (Commission         I.R.S. Employer
of Incorporation)                  File Number)      Identification No.)

                614 Mckinley Place NE
                   Minneapolis, MN                       55413
       (Address of Principal Executive Offices)       (Zip Code)

     Registrant's telephone number, including area code:  (612) 379-8854

                              Not Applicable
      (Former Name or Former Address, if changed since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any
of the following provisions:

/ /   Written communications pursuant to Rule 425 under the Securities Act
      17 CFR 230.425)

/ /   Soliciting material pursuant to Rule 14a-12 under the Exchange Act
      (17 CFR 240.14a-12)

/ /   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

/ /   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))






Item 8.01  Other events

A copy of a press release issued by Techne Corporation on June 10, 2009,
announcing the receipt of two scientific awards by a member of its
Board of Directors, is attached hereto as Exhibit 99.1.



Item 9.01 Financial Statements and Exhibits

     (d) Exhibits

          99.1 Press Release dated June 10, 2009.






                            SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Dated: June 10, 2009                  TECHNE CORPORATION

                                      By: /s/ Thomas E. Oland
                                      ---------------------------
                                      Name: Thomas E. Oland
                                      Title: President and Chief
                                        Executive Officer




                          EXHIBIT INDEX

    Exhibit No. Description
    ----------- -----------
       99.1     Press release of Techne Corporation dated June 10, 2009.

EX-99.1

                        TECHNE CORPORATION BOARD MEMBER RECOGNIZED


Minneapolis/June 10, 2009/  Charles A. Dinarello, M.D., a Professor of
Medicine at the University of Colorado School of Medicine in Denver and a
member of the Techne Corporation Board of Directors, was recently recognized
with two distinguished awards.

On April 26, 2009, Dr. Dinarello, Ralph M. Steinman, M.D., of Rockefeller
University and Bruce Beutler, M.D., of The Scripps Research Institute, were
the 2009 recipients of the Albany Medical Center Prize in Medicine and
Biomedical Research for their "groundbreaking discoveries that have
transformed the field of immunology."  The Prize is the largest award in
medicine or science in the United States.

James J. Barba, president and chief executive officer of Albany Medical
Center, who served as chairman of the National Selection Committee, in an
April press release, said, "Collectively, the work of these scientists has
led to a dramatically better understanding of the human immune system, in
health and in disease.  That knowledge has already directly resulted in new
therapies for people with conditions including rheumatoid arthritis,
diabetes, Crohn's disease and cancer. And, the discoveries they have made
about how the body senses and responds to infection remain the basis of
active research that holds the promise of new and improved vaccines and
innovative ways to harness the power of the immune system to better fight
viruses and bacterial illness. Their achievements are nothing short of
astounding."

Dr. Dinarello, along with Professors Tadamitsu Kishimoto, M.D., Ph.D., and
Toshio Hirano, M.D., Ph.D., both of Japan, have been named Crafoord Laureates
2009 and were honored by the Royal Swedish Academy of Sciences in ceremonies
on May 11, 2009 in Stockholm, Sweden.  The laureates received their prize
medals from the King of Sweden, Carl Gustav the 16th.  The 2009 Crafoord Prize
was awarded "for their pioneering work to isolate interleukins, determine
their properties and explore their role in the onset of inflammatory
diseases."  This year's Crafoord Prize laureates discovered two new key
players in the immune  system of the  human body:  the signal substances
interleukin-1 (IL-1)  and interleukin-6  (IL-6). Child and adult joint-
disease sufferers often have high concentrations of these substances in their
bodies. Activated by these substances, the immune system then starts to break
down cartilage and bone.  The Crafoord Prize in astronomy and mathematics,
biosciences, geosciences or polyarthritis is awarded by the Royal Swedish
Academy of Sciences annually according to a rotating scheme. The Crafoord
prize is one of the world's largest scientific prizes.

Tom Oland, President and Chief Executive Officer of Techne Corporation,
stated that "the shareholders and employees of the Company are very fortunate
to benefit from Dr. Dinarello's extraordinary experience and commitment to
science.  Dr. Dinarello has been helpful to the Company and its scientists
for many years.  On their behalf, we offer sincerest congratulations for
these well-deserved recognitions."

                *  *  *  *  *  *  *  *  *  *  *  *  *  *

Techne Corporation has two operating subsidiaries:  Research and Diagnostic
Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe,
Ltd. (R&D Europe) of Abingdon, England.  R&D Systems is a specialty
manufacturer of biological products.  R&D Systems has two subsidiaries,
BiosPacific, Inc. (BiosPacific), located in Emeryville, California and R&D
Systems China Co. Ltd., (R&D China), located in Shanghai, China.  BiosPacific
is a worldwide supplier of biologics to manufacturers of in vitro diagnostic
systems and immunodiagnostic kits. R&D China and R&D Europe distribute
biotechnology products.

Contact:  Greg Melsen, Chief Financial Officer
         (612) 379-8854